Nidhi Saxena

Biography

All India Management Association (AIMA), the apex body for management in India. She took charge of AIMA in June 2008. She is a member of the Indo-Netherlands Joint Working Group on Corporate Governance and Corporate Social Responsibility set up by the Ministry of Corporate Affairs, Government of India. She is also a member of the Advisory Board of the Switzerland based St Gallen Foundation think tank, Leaders of Tomorrow – Knowledge Pool. Prior to joining AIMA, Ms. Sethi had worked with the Confederation of Indian Industry (CII) for over 17 years.Physico-Chemical property profiling: Thermodynamic solubility, LogD, LogP, pKa, PAMPA, and chemical stability test. Chiral Separation: Chiral prep HPLC and chiral analytical GC.Recruiting, Mentoring and Team Building • Global Pharmaceutical and Medical Device Sales and Marketing Networks startup and management • Brand/Generic Prescription, OTC & Medical Device Sales Networks in US, Asia & Europe • Partner with non-profit foundations in funding rare disease research and clinical programs and implementing donation programs within corporations. • Expatriate Residence: Hong Kong, Japan, Singapore • Language: Japanese

Research Interest

Pharmaceutical science,pharmacovigilance ,Analytical chemist, separation science, mass spectrometry, and wet chemistry. Chiral/achiral analytical method development. Chiral/achiral purification. GMP trained. Pre-clinical formulation. Lab automation. ï‚Ÿ UPLC, SFC, GC, LC/MS, LC/MS/MS (Q-TOF), ICP-MS, and GC/MS ï‚Ÿ Lab automation and analytical system integration ï‚Ÿ Instrument trouble-shooting/repair ï‚Ÿ Extensive experience in LC and MS data processing software development ï‚Ÿ Waters Empower and Waters NuGenesis SDMS system administration ï‚Ÿ Program skills: java, C#, VB, Oracle SQL, Waters Empower custom field, Waters Empower Toolkit, Agilent ChemStation Macro, Waters MassLynx DAC, and Waters NuGenesis SDMS Toolkit.Therapeutic Specialties: Infectious disease, pain & inflammation, ophthalmology, oncology, cardiovascular, orphan indications, and a quick learner for any other therapeutic areas.